A Multi-Institutional Phase II Study of the Akt Inhibitor MK-2206 in Refractory Biliary Cancers.
Phase of Trial: Phase II
Latest Information Update: 19 Jun 2016
At a glance
- Drugs MK 2206 (Primary)
- Indications Biliary cancer; Gallbladder cancer; Liver cancer
- Focus Therapeutic Use
- 22 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 15 Jan 2014 Planned End Date changed from 1 Jan 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
- 14 Feb 2013 Planned end date changed from 1 Jan 2012 to 1 Jan 2014 as reported by ClinicalTrials.gov.